...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Message: Apabetalone and Alkaline Phosphatase
After reading the upcoming ASN abstracts and reviewing the past publications and presentations about apabetalone and alkaline phosphatase, I am extremely excited about apabetalone's potential in not just cardiovascular disease, but also for cognition, kidney function and other diseases.
There seems to be a solid connection to alkaline phosphatase (as well as inflammation) connected to these diseases. From one of the ASN abstracts (bracket text added by me):"Elevated ALP [alkaline phosphatase] is associated with poorer cognitive function and greater prevalence of CKD [as well as CVD]". "Approximately half of the [BETonMACE CKD sub-study] population showed MoCA score <26 suggesting early cognitive impairment. Lower MoCA score was associated with: a) higher ALP, and, b) with presence of CKD." So these diseases (CVD, cognition, CKD) don't operate independently but seem to cluster together and are associated with alkaline phosphatase levels. In pooled analysis of the Phase 2 trials, the most significant (p<0.0001) effect on reported calcification, lipid and inflammation markers was on alkaline phosphatase. Even more significant than effects on apo-AI, HDL-C, and hsCRP. So maybe, just maybe, there is something to this alkaline phosphatase story........
I've compiled abstracts, publications, presentations and posters below for your weekend enjoyment.
ASN and AHA abstracts:
ERA-EDTA 2018 and 2019 Symposia Presentations (full list here):
BETonMACE CKD Sub-study
BETonMACE Chronic Kidney Disease Sub-Study: Effects of the Selective BET-Inhibitor Apabetalone on Kidney Function and MACE in Post-ACS Patients with Diabetes and Estimated Glomerular Filtration Rate Below 60
Please login to post a reply